Delving into the Latest Updates on ZM001 with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms

ZM001

Target-

Mechanism-

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication

Systemic Lupus Erythematosus

Inactive Indication-

Originator Organization

Xiamen Zaimiao Biotechnology Co., Ltd.

Active Organization

Beijing Imunopharm Technology Co., Ltd.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Primary objective: To evaluate the safety of ZM001 in the treatment of patients with refractory systemic lupus erythematosus and determine the recommended Phase II dose (RP2D) of ZM001. Secondary objectives: The effect of ZM001 reinfusion on the clinical disease activity of the subjects, the changes in the subjects' quality of life, the status of anti-drug antibodies, and the pharmacokinetic and pharmacodynamic characteristics

Start Date-

Sponsor / Collaborator

Xiamen Zaimiao Biotechnology Co., Ltd.

100 Clinical Results associated with ZM001

Login to view more data

100 Translational Medicine associated with ZM001

Login to view more data

100 Patents (Medical) associated with ZM001

Login to view more data

100 Deals associated with ZM001

Login to view more data